These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15598037)

  • 1. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
    Hilger RA; Baumgart J; Scheulen ME; Trenschel R; Strumberg D; Seeber S; Beelen DW
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):654-5. PubMed ID: 15598037
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
    Galaup A; Paci A
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):333-47. PubMed ID: 23157726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
    Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
    Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
    ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
    Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation.
    Casper J; Freund M
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):661-2. PubMed ID: 15598040
    [No Abstract]   [Full Text] [Related]  

  • 10. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
    Romański M; Wachowiak J; Główka FK
    Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
    Danylesko I; Shimoni A; Nagler A
    Bone Marrow Transplant; 2012 Jan; 47(1):5-14. PubMed ID: 21478921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
    Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
    Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
    J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan and metronidazole: an often forgotten but significant drug interaction.
    Gulbis AM; Culotta KS; Jones RB; Andersson BS
    Ann Pharmacother; 2011 Jul; 45(7-8):e39. PubMed ID: 21730282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
    Corker E; Astwood E; Williams J; Vora A
    Br J Haematol; 2012 Oct; 159(1):104-6. PubMed ID: 22804487
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
    Główka FK; Łada MK; Grund G; Wachowiak J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.